Close Menu

Biocartis

Biocartis this week named Nayan Gregory Parekh as the company's new CEO, replacing current CEO Rudi Pauwels.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Swiss molecular diagnostics company Biocartis today announced it has completed its Series C equity financing round, raising €71 million ($96 million).

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.

The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.

BioMerieux, an Affymetrix diagnostics partner, will use the Affy platform for R&D, but "not for tests that we commercialize."

Diagnoplex received a boost toward commercializing its flagship PCR-based colon cancer blood test in the form of a "substantial" Series A financing extension by fellow Swiss biopharmaceutical conglomerate Debiopharm Group.

Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.

Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.

The fund called Advent Life Sciences is the first from Advent focusing on life sciences.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.